United States Patent 7,968,559 (Method of Treating IBS and Carcinoid Syndrome): Scope, Claim Boundaries, and US Patent Landscape
United States Patent 7,968,559 claims broad method-of-treatment coverage for irritable bowel syndrome (IBS) and carcinoid syndrome, defined by administration of a family of compounds having a general structural formula with wide substitutional variability (multiple positions, multiple substituent classes, and substituent-count ranges such as m = 1–4 and n = 1–3, p = 1–4, q = 1–2).
The claim set is product-agnostic on dosage form and route (no limitations on formulation, delivery, or excipients) and uses generic chemical-class language (halogen, C(O)RA, ORA, NRBRC, S(O2)RA, and substituted alkyl/aryl/heterocycle). The practical enforcement boundary is driven by (i) whether the accused compound falls within the covered Markush ranges at each variable position, and (ii) whether it is administered for IBS or for carcinoid syndrome.
The text provided contains the claim framework, but it does not include the actual chemical formula drawings/structures embedded in the claim text (the formula placeholders are present but not fully reproduced), nor does it provide patent bibliographic data (assignee, filing date, issuance date already implied by number, priority claims, or cited art). Without those elements, a complete landscape mapping across related US continuations, divisional family members, and Orange Book entries cannot be produced with high integrity.
What patents protect methods of treating IBS under US 7,968,559?
What is the independent claim scope (Claim 1) for IBS?
Claim 1 is an IBS method claim that covers administering, to a patient with IBS, a therapeutically effective amount of a compound of a general formula or a pharmaceutically acceptable salt.
Key scope levers inside Claim 1:
- Indication tie-in: “treating irritable bowel syndrome” (method-of-use limitation).
- No delivery constraints: no specified route, dosing frequency, or formulation.
- Core definition is structural Markush variability:
- A1: optionally substituted heterocycle (substituent generality).
- R1, R2: each independently chosen from
halogen, hydrogen, C(O)RA, ORA, NRBRC, S(O2)RA, or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle.
- R3: hydrogen, C(O)RA, C(O)ORA, or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle, aryl, or heterocycle.
- R4: hydrogen or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle, aryl, or heterocycle.
- RA/RB/RC: each independently hydrogen or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle.
- m: integer 1 to 4, limiting the number (or occurrence) of a substituent class at a defined set of positions within the base scaffold.
Interpretation in enforcement terms: An accused compound must match the overall scaffold implied by the “formula” and also satisfy the substitution constraints at each variable position. Because R1/R2 allow broad classes (carbonyl-containing substituents, ethers, tertiary amide-like/amine-like patterns via NRBRC, and sulfone-bearing S(O2)RA), the “chemical space” covered is large.
How do dependent Claims 9–13 narrow Claim 1 for IBS?
Claims 9–13 lock down specific subsets:
- Claim 9: R1 is hydrogen or halogen.
- Claim 10: m = 1.
- Claim 11: R2 is hydrogen or amino.
- Claim 12: R3 is hydrogen or lower alkyl.
- Claim 13: R4 is hydrogen or lower alkyl.
These dependent claims are not substitutes for the independent claim. They create additional, narrower fences that can be asserted if an accused compound sits inside only a partial slice of the broader Markush space.
When does US 7,968,559 lose exclusivity for IBS?
A determinative exclusivity timeline requires the patent’s filing date, priority date, and whether it has terminal disclaimers, PTA, or related overlapping patents. That data is not included in your input.
What can be stated from the claim structure alone:
- The patent’s claims are method-of-treatment claims, not formulation or dosing-regimen claims. For generic entry risk analysis, the key is whether a generic’s product label and promotional use is tied to IBS/carсinoid syndrome and whether the generic’s active is within the claimed compound class.
- If there are additional patents covering the specific active compound(s) or salt form(s), those patents may control exclusivity even if this method-of-use patent is outside its term.
No claim text here supports a computable “loss date” without bibliographic data.
What is the scope of US 7,968,559 for carcinoid syndrome?
What is the independent claim scope (Claim 17) for carcinoid syndrome?
Claim 17 is parallel to Claim 1 but for carcinoid syndrome. It also covers administration of a compound of a general formula with the following variable definitions:
- A1: optionally substituted heterocycle.
- R1, R2: same broad classes as Claim 1 (halogen/hydrogen/C(O)RA/ORA/NRBRC/S(O2)RA/alkyl(aryl/heterocycle)-type substitutions).
- R3: hydrogen, C(O)RA, C(O)ORA, or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle, aryl, or heterocycle.
- R4: hydrogen or optionally substituted alkyl/alkyl-aryl/alkyl-heterocycle, aryl, or heterocycle.
- RA/RB/RC: hydrogen or substituted alkyl families.
- m: 1–4.
The carcinoid claim set includes dependent subclauses that mirror the IBS ones, including multiple sub-formula recitations with parameters n, p, and q.
How do dependent Claims 25–29 narrow the carcinoid scope?
- Claim 25: R1 is hydrogen or halogen.
- Claim 26: m = 1.
- Claim 27: R2 is hydrogen or amino.
- Claim 28: R3 is hydrogen or lower alkyl.
- Claim 29: R4 is hydrogen or lower alkyl.
How broad are the Markush ranges and what do they mean for design-around risk?
Variable-position breadth
The claim language is permissive:
- R1 and R2 each accept six broad substituent families plus “optionally substituted” variants.
- R3 accepts both “simple” options (hydrogen) and more complex carbonyl patterns (C(O)RA and C(O)ORA) and large aromatic/heterocyclic options.
- R4 accepts hydrogen or a wide range of optionally substituted groups.
This creates high coverage odds for many plausible medicinal chemistry variants, particularly where the base scaffold is the same and substitutions fall within the listed families.
Numerical parameters (m, n, p, q)
Claims 1 and 17 use m = 1–4. Dependent claims also mention sub-formulas with n = 1–3, p = 1–4, q = 1–2.
From an infringement/design-around perspective, integer-bound parameters can be narrower than substituent choices. A design-around that keeps the same scaffold but changes the number of substituents counted by m/n/p/q could fall outside the literal scope.
Because the actual drawings are not included, the precise mapping of which ring positions are counted by m/n/p/q cannot be reconstructed. The boundary remains: if the accused structure’s “count variable” does not satisfy the integer range, it is a potential literal avoidance route.
What formulations are protected by US 7,968,559?
The provided claims do not limit:
- dosage form (tablet, capsule, injection, etc.)
- route (oral, subcutaneous, etc.)
- release profile (immediate vs extended)
- excipient composition
- pharmacokinetic targets
This is a pure method-of-use claim tied to “administering a therapeutically effective amount” of a covered compound to treat IBS or carcinoid syndrome.
If enforcement depends on the method claim, the defendant’s infringement analysis will focus on:
- whether the administered active falls in the compound formula,
- and whether the administration is for IBS or carcinoid syndrome (including label and promotional “indication” issues).
How strong is the patent estate for IBS/carcinoid methods around US 7,968,559?
A credible “patent estate strength” analysis requires:
- the assignee,
- priority chain,
- prosecution history (amendments narrowing or not),
- related continuation/divisional patents,
- and whether there are companion US patents on the same compound(s) (composition-of-matter) or other related method claims.
Your input provides only the claim text. It does not provide bibliographic identity, assignee, or claim-construction context. Under strict completeness constraints, a quantified strength assessment across the estate cannot be generated from the current data.
What generic entry risks exist for IBS or carcinoid syndrome tied to this method claim?
Risk driver #1: compound inclusion
If a generic manufacturer’s active compound falls outside the covered Markush ranges (including the m/n/p/q constraints), the method claim is not triggered.
If the active is inside the formula, the generic is vulnerable on method-of-use theory, but enforcement still needs the second driver:
Risk driver #2: “for IBS” or “for carcinoid syndrome”
Even with a covered compound, method-of-use infringement often turns on:
- the FDA-approved indication for the product,
- labeling language and promotional materials.
This claim’s broad language (“treating IBS” and “treating carcinoid syndrome”) means indication-specific conduct matters.
Because the claim is not limited by dosing regimen, a generic that is prescribed for IBS or carcinoid syndrome using the covered compound could be exposed if the jurisdiction recognizes method-use infringement under those facts.
Which companies are challenging or licensing around US 7,968,559?
No entity-specific information is included in your input (no applicant/assignee, no litigation captions, no FDA product mappings, no Orange Book entries). A company-by-company challenge or licensing analysis would require those data points, and cannot be produced from the claim text alone.
Key Takeaways
- US 7,968,559 covers methods of treating IBS and carcinoid syndrome by administering therapeutically effective amounts of a broad Markush-defined compound family (multiple variable positions with wide substituent classes and integer range constraints).
- No formulation or dosing limitations appear in the provided claims, increasing the breadth of method-use coverage.
- Dependent claims narrow specific substitution scenarios (R1 hydrogen/halogen; m = 1; R2 hydrogen/amino; R3 hydrogen/lower alkyl; R4 hydrogen/lower alkyl), creating multiple narrower “fallback” scopes.
- Design-around likelihood turns on whether an accused structure satisfies each variable position and m/n/p/q integer constraints, not on dosage-form changes.
- Exclusivity timelines, Orange Book status, and landscape strength cannot be completed from the supplied claim text alone because filing/priority, assignee, and family/litigation data are absent.
FAQs
-
Does US 7,968,559 require a specific dosage form or route of administration?
No. The claims require administering a therapeutically effective amount of a covered compound; no formulation or route limits are stated in the provided claim text.
-
Can a manufacturer design around by changing only R4?
Potentially, because dependent claims define subsets (e.g., R4 hydrogen or lower alkyl), but literal avoidance depends on whether the accused compound matches the full independent-claim Markush definition at every variable position and satisfies m/n/p/q constraints.
-
Is the indication limitation strict (IBS vs carcinoid syndrome)?
Yes. Claim 1 is for IBS; Claim 17 is for carcinoid syndrome. Infringement theories tied to these claims generally require administration “for” the claimed indication.
-
Do the claims cover salts?
Yes. Each claim covers the compound and “pharmaceutically acceptable salts thereof.”
-
Are method claims typically enforceable against generic prescribing even without generic label language?
Enforcement outcomes depend on jurisdiction-specific method-of-use infringement doctrines and evidence of “for” the claimed indication. The claim text itself does not limit enforcement to labeled indications, but practical risk often tracks labeling/promotion.
References
- United States Patent 7,968,559 (claim set provided in prompt text).
